USA flag logo/image

An Official Website of the United States Government

Controlling Inflammation Due to Cardiac Devices

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R44HL099015
Solicitation Year:
2011
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA09-080
Small Business Information
NOVELMED THERAPEUTICS, INC.
11000 Cedar Avenue, 135 CLEVELAND, OH 44106-0000
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: Yes
 
Phase 2
Fiscal Year: 2011
Title: Controlling Inflammation Due to Cardiac Devices
Agency: HHS
Contract: 4R44HL099015-02
Award Amount: $1,352,967.00
 

Abstract:

DESCRIPTION (provided by applicant): NovelMed's lead drug candidate prevents biomaterials induced cellular activation. Activated cells release inflammatory mediators that are responsible for pathological trauma that leads to cardiac, lung, liver, and braininjuries during surgical procedures that require cardiac devices. Our findings provide convincing support for developing YalcixiMab as a treatment to prevent biomaterial-induced inflammation that occurs during surgical procedures. CPB circuits are used during various procedures for heart transplant, and valve replacements. Treatment of blood with YalcioMab prior to the extracorporeal circulation prevents complement activation, neutrophil activation, monocyte activation, platelet activation and the formation of leukocyte-platelet aggregates. The drug also prevents the release of potent inflammatory mediators such as TNF-1. . PUBLIC HEALTH RELEVANCE: NovelMed is developing treatments that will reduce/prevent complications that arise when blood is exposed to biomaterial surfaces of the cardiac devices. Cardiopulmonary bypass circuits are utilized in several cardiac surgeries as a heart-lung machine while surgeons perform procedures on the empty heart. The ultimate objective of this proposal is the development of technologies that will improve the manufacturing of engineered human tissues

Principal Investigator:

Rekha Bansal
440-477-9874
rekha@novelmed.com

Business Contact:

Rekha Bansal
216-707-1776
rekha@novelmed.com
Small Business Information at Submission:

NOVELMED THERAPEUTICS, INC.
2265 ENTERPRISE PKWY TWINSBURG, OH 44087-2337

EIN/Tax ID: 142159780
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No